The Epstein-Barr virus (EBV) is a ubiquitous virus that causes infectious mononucleosis in people with normal immune function; however, in immunocompromised patients such as those undergoing hematopoietic cell or solid organ transplants, it can cause lymphoma and other cancers. EBV-CTLs are a potential third-party, donor-derived, off-the-shelf T-cell product candidate designed to target and destroy EBV-infected lymphoma cells.

    EBV-CTLs are being studied in an ongoing Phase 2 clinical trial to test anti-tumor efficacy and safety in patients with EBV-associated lymphoproliferative disease (EBV-LPD) following allogeneic hematopoietic cell transplant (alloHCT). AlloHCT is a transplant of bone marrow stem cells from one person to another as a means to treat a variety of serious diseases, primarily blood cancers.